Insights / Resource Center
Resources
Scientific Posters
Events
Primrose Bio presents at the mRNA-Based Therapeutics Summit 2025: Enhancing RNA Polymerase Performance
September 23 – 25, Primrose Bio joins the 2025 mRNA Therapeutics Summit in Boston to present RNA polymerase innovations for scalable, high-quality mRNA manufacturing.
Primrose Bio at AMM Ascent 2025: Advancing mRNA Manufacturing
September 16 – 18, Primrose Bio attends AMM Ascent 2025 to present RNA polymerase innovation and connect with leaders advancing mRNA manufacturing.
Primrose Bio at BIO International Convention 2025
June 16–19, Primrose Bio joined BIO 2025 in Boston to showcase innovations in RNA polymerase, protein expression, and CRM197 carrier protein for next-gen therapeutics.
Webinars
Pfast™ Protein Expression
Achieving High Quality Efficient mRNA Synthesis
Scientific Posters
Presented at TIDES USA 2025: Prima RNApols™ ExTend: rewriting the rules of long mRNA manufacturing
ABSTRACT: The success of mRNA COVID-19 vaccines has transformed the therapeutic landscape, accelerating the development of mRNA-based treatments across diverse applications. While in vitro...
Presented at TIDES USA 2025: Advancing mRNA therapeutics with high performance RNA polymerases
ABSTRACT: RNA has emerged as a critical tool in modern biotechnology and therapeutics, with applications ranging from vaccine development to gene therapy. mRNA is synthesized by in vitro...
Presented at PEGS US 2025: High-Throughput Expression and Purification of Untagged RNA Polymerase Variants: Advancements in the Pfenex Expression Technology® Platform
ABSTRACT: Primrose Bio's Pfenex Expression Technology® (Pfenex) platform has established itself as a robust, scalable solution for recombinant protein production, as evidenced by its role in six...
Case Studies
Pfenex
Recombinant Erwinia Asparaginase Production
Acute lymphoblastic leukemia (ALL) is the most common type of cancer in children. Lymphoblastic lymphoma (LBL) is a rare, fast-growing, aggressive subtype of non-Hodgkin’s lymphoma most often seen in teenagers and young adults.
Pfenex
Production of disulfide-rich cow knob domain antibodies: picobodies™
About 10% of cow antibodies have exceptionally long heavy chain CDR3 regions, including a stalk and knob region.
Pfenex
Multimeric vhh nanobody expression
Pfenex
Fab antibody fragment titer improvement
Anti-IL-4 Conjugate Vaccine Prepared with PeliCRM197 is More Immunogenic than KLH Analog
Comparable Immunogenicity Observed in Peptides Coupled to PeliCRM197 and KLH in a Murine Model
In this case study, 3 peptides (peptides #5, #6, and #7) directed to one therapeutic target were conjugated to either CRM197 (a non-toxic diphtheria toxin mutant) produced with Pfenex Expression Technology® or to KLH (keyhole limpet hemocyanin).